Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Multiple Myeloma Market?

The market for multiple myeloma has seen significant upturn over the past few years. Displaying considerable growth, it is projected to scale up from $26.07 billion in 2024 to $28.05 billion in 2025, representing a compound annual growth rate (CAGR) of 7.6%. Factors promoting the growth through the historic period include enhancements in diagnostics, the advent of stem cell transplantation, availability of superior medical care, precision medicine strategies, and patient-focused care structures.

In the forthcoming years, the multiple myeloma market size is anticipated to experience robust growth, reaching $38.16 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.0%. This prospective rise during the forecast period can be credited to the assimilation of health technology, the uptake of telemedicine services, bespoke vaccine therapies, and digital health platforms intended for patient knowledge enhancement. The notable trends projected in the forecast period involve progress in targeted therapies, the creation of new drugs, improvements in immunotherapy, the development of novel biomarkers, and the incorporation of artificial intelligence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

What Core Drivers Are Expected To Influence The Multiple Myeloma Market?

The continuous surge in incidences of multiple myeloma is anticipated to bolster the expansion of the multiple myeloma market in the future. Multiple myeloma is a type of cancer that originates in plasma cells, a certain kind of white blood cells. The reason behind the upsurge in multiple myeloma cases can be traced to factors like aging, genetic predisposition, obesity, exposure to radiation, and various other conditions. Treatments for multiple myeloma impede its progression and alleviate the symptoms. As an example, the American Cancer Society, a voluntary health organization from the US, reported that the new cases of multiple myeloma escalated to 35,730 in 2023 from 34,470 in 2022. In light of this, the growing incidence of multiple myeloma plays a significant role in propelling the multiple myeloma market’s development.

Which Segmentation Categories Are Highlighted In The Multiple Myeloma Market Analysis?

The multiple myelomamarket covered in this report is segmented –

1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments

2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests

3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs); Proteasome Inhibitors; Monoclonal Antibodies; Corticosteroids; Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT); Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care; Clinical Trials And Experimental Therapies

Which Trends Are Likely To Redefine Growth Paths In The Multiple Myeloma Market?

Leading the multiple myeloma market, product innovation has emerged as a significant trend. Various dominant businesses in this market are investing in the development of unique products to maintain their market standing. For example, in October 2022, TECVAYLI (teclistamab-cqyv), the pioneering bispecific T-cell engager antibody, achieved approval from the US Food and Drug Administration (FDA). This approval was granted to Janssen Pharmaceutical Companies of Johnson & Johnson, headquartered in Belgium. The medication is specifically designed for adult patients with multiple myeloma who have undergone at least four prior therapy lines, including proteasome inhibitors, immunomodulatory drugs, and CD38 antagonistic monoclonal antibodies. Its function lies in targeting the B-cell maturation antigen (BCMA), which is noticeable on some healthy B-lineage cell surfaces, as well as the CD3 receptor noticeable on T-cells and multiple myeloma cells surfaces.

Who Are The Dominant Players In The Multiple Myeloma Market Today?

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Multiple Myeloma Market?

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12163&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Market 2025, By The Business Research Company

Amusement Parks Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/amusement-parks-global-market-report

Spa Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spa-global-market-report

Low Speed Electric Vehicle Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/low-speed-electric-vehicle-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model